Cargando…
Atorvastatin Restores PPARα Inhibition of Lipid Metabolism Disorders by Downregulating miR-21 Expression to Improve Mitochondrial Function and Alleviate Diabetic Nephropathy Progression
Atorvastatin is a classical lipid-lowering drug. It has been reported to have renoprotective effects, such as reducing urinary protein excretion and extracellular matrix aggregation. The present study aimed to investigate the specific mechanism of action of Atorvastatin in type 1 diabetic mice (T1DM...
Autores principales: | Xiang, Jiayi, Zhang, Huifang, Zhou, Xingcheng, Wang, Dan, Chen, Rongyu, Tan, Wanlin, Liang, Luqun, Shi, Mingjun, Zhang, Fan, Xiao, Ying, Zhou, Yuxia, Wang, Yuanyuan, Guo, Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874267/ https://www.ncbi.nlm.nih.gov/pubmed/35222033 http://dx.doi.org/10.3389/fphar.2022.819787 |
Ejemplares similares
-
Senescent renal tubular epithelial cells activate fibroblasts by secreting Shh to promote the progression of diabetic kidney disease
por: Wang, Dan, et al.
Publicado: (2023) -
BMP-7 ameliorates partial epithelial-mesenchymal transition by restoring SnoN protein level via Smad1/5 pathway in diabetic kidney disease
por: Peng, Wei, et al.
Publicado: (2022) -
The role of CDX2 in renal tubular lesions during diabetic kidney disease
por: Liu, Huiming, et al.
Publicado: (2021) -
Metrnl Alleviates Lipid Accumulation by Modulating Mitochondrial Homeostasis in Diabetic Nephropathy
por: Zhou, Yuxia, et al.
Publicado: (2023) -
Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPARα
por: Chen, Qian, et al.
Publicado: (2017)